Postagens
#ASCO 2017 A randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab, a PD-L1 antibody, to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC).
- Gerar link
- X
- Outros aplicativos
#ASCO2017 EarlyR genomic signature to predict pathological complete response following neoadjuvant anthracycline-taxane chemotherapy in estrogen-receptor positive (ER+) breast cancer.
- Gerar link
- X
- Outros aplicativos
#ASCO 2017 BIOSIMILARES DE TRASTUZUMAB EM NEOADJUVANCIA RESULTADOS 5,1% SUPERIORES QUE USUAL
- Gerar link
- X
- Outros aplicativos
#ASCO 2017 Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2.
- Gerar link
- X
- Outros aplicativos
#ASCO 2017 Pembrolizumab (pembro) + chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): Preliminary results from KEYNOTE-173.
- Gerar link
- X
- Outros aplicativos
#ASCO2017 Effect of TCHL-based therapy on immune cell content in on-treatment, neoadjuvant-treated HER2-positive breast cancer patients, APÓS 1o CICLO DE TRATAMENTO TILS PARECE SER UM BOM PREDCITOR DE RESPOSTA PATOLOGICA MAS SLs NÃO
- Gerar link
- X
- Outros aplicativos